Pharma Turkey Dergisi Eylül – Ekim 2017 Sayısı

Drug used in the treatment of rheumatoid
arthritis to be produced in Turkey
The newly developed drug in the treatment of “rheumatoid arthritis” (RA),
inflammatory joint disease that causes joint damage and can keep the system
with many organs, will now be produced in Turkey as well as in Japan
The drug “Iguratimod”, which has
been developed as a new option
for patients, will be made available
to physicians and patients in 21
countries in the Middle East and
Africa, following the completion
of the licensing and medication
process carried out by the domestic
pharmaceutical company TRPharm.
The “Iguratimod” active ingredient
anti-rheumatic drug developed
by Toyama Chemical and Eisai in
Japan and used in the treatment of
rheumatoid arthritis patients was also
produced in Turkey and a business
partnership was established with the
domestic pharmaceutical company
in order to be able to import to many
countries.
The domestic pharmaceutical
company took action for licensing,
production and marketing of the drug
in Turkey and the Middle East-North
Africa (MENA) region.
As a result of the business
partnership, the product was
identified as a production center
outside of Japan in global markets
and the required technology transfer
was realized. The drug will be supplied
from Turkey to 21 countries after the
licensing process is completed.
“Turkey will be further strengthened
in the pharmaceutical sector”
TRPharm General Manager
Mehmet Goker said that Turkey is
very important, saying that Turkey
has entered the International
Pharmaceutical Inspection
Association (PIC / S) where
the leading countries of the
pharmaceutical industry are also
located.
Stating that Turkey has a high
potential in terms of original drug
exports, Goker said, “The step taken
by Iguratimod active drug will be
increasing. Turkey will become
an important place in the
world in drug development,
production and marketing in
the near future. The support
provided by the local firm
is encouraging. As domestic
production increases, Turkey will
become stronger every day in the
pharmaceutical sector.”
Declaring that Turkey’s selection of
the second production center for the
drug is very important, Goker said,
“Our country will meet the needs
of approximately 21 countries in the
Middle East and African countries
after the process of licensing and
pajama.”
He emphasized that many domestic
pharmaceutical companies have
been left behind by the government’s
incentive policies and that they have
signed important cooperations. Over
time, Goker believes that Turkey
believes that this area will have a
place until the establishment of R & D
centers equipped with production and
high technology from new molecule
development.
Mehmet Goker said, “The drug will be
supplied from Turkey to 21 countries
after the completion of the licensing
processes. Drugs manufactured in
Turkey by TRPharm and approved in
Lebanon will enter service in Saudi
Arabia, Qatar and BAE.”
Rheumatoid arthritis most
commonly seen between 20 and 40
years
TRPharm General Manager
Mehmet Göker
Rheumatoid
arthritis is defined as “a chronic,
inflammatory disorder that causes the
patient’s immune system to attack the
various joints of the body.”
The disease can cause significant loss
of motion due to pain and abrasion
in the joints. It is often considered a
systemic disease because it affects
many extraarticular tissues such as
skin, blood vessels, heart, lungs and
muscles in the body. Rheumatoid
arthritis, as it may occur at any age, is
most commonly seen in the 20-40 age
range. Genetic factors are important
in disease development. While risk
increases in first-degree relatives, the
probability of single-egg twins is 10
times higher.
The disease is three times more
common in females than males and
four times more common in smokers
than in non-smokers.
Pharma
September- October ‘17 41